Simultaneous quantification of nicotine, cotinine, trans-3'-hydroxycotinine, norcotinine and mecamylamine in human urine by liquid chromatography-tandem mass spectrometry

Clinica Chimica Acta

Volumn 413, Issue 11-12, 2012, Pages 978-984

  Scheidweiler, Karl B ^a   Shakleya, Diaa M ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Cotinine; LCMSMS; Mecamylamine; Nicotine; Trans 3' hydroxycotinine; Urine

Indexed keywords

3' HYDROXYCOTININE; COTININE; MECAMYLAMINE; NICOTINE; NORCOTININE; UNCLASSIFIED DRUG;

ARTICLE; DRUG URINE LEVEL; ELECTROSPRAY; ENVIRONMENTAL EXPOSURE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; THERMOSTABILITY; URINALYSIS;

CALIBRATION; CHROMATOGRAPHY, LIQUID; COTININE; HUMANS; MECAMYLAMINE; NICOTINE; SENSITIVITY AND SPECIFICITY; SMOKING; SMOKING CESSATION; TANDEM MASS SPECTROMETRY;

EID: 84859431642     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.02.017     Document Type: Article

References (33)

1. Substance Abuse and Mental Health Services Administration, Results from the 2009 National Survey on Drug Use and Health: National Findings In: Office of Applied Studies, editor. NSDUH Series H-38A. Rockville, MD: Department of Health and Human Services (DHHS), 2010.
2. Centers for Disease Control and Prevention, Smoking & Tobacco Use. Fast facts 2011, Centers for Disease Control and Prevention, Atlanta, GA, Available at:, Accessed February 9, 2012. http://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm.
3. Yildiz D. Nicotine, its metabolism and an overview of its biological effects. Toxicon 2004, 43:619-632.
4. Bergen A.W., Caporaso N. Cigarette smoking. J Natl Cancer Inst 1999, 91:1365-1375.
5. Lackmann G.M., Salzberger U., Tollner U., Chen M., Carmella S.G., Hecht S.S. Metabolites of a tobacco-specific carcinogen in urine from newborns. J Natl Cancer Inst 1999, 91:459-465.
6. Henningfield J.E., Fant R.V., Buchhalter A.R., Stitzer M.L. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 2005, 55:281-299. quiz 322-3.
7. Silagy C., Lancaster T., Stead L., Mant D., Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004, (3). Art. No.: CD000146. DOI: 000110.001002/14651858.CD14000146.pub14651852.
8. Palmer K.J., Buckley M.M., Faulds D., et al. Transdermal nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992, 44:498-529.
9. Sachs D.P., Sawe U., Leischow S.J. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med 1993, 153:1881-1890.
10. Westman E.C., Levin E.D., Rose J.E. The nicotine patch in smoking cessation. A randomized trial with telephone counseling. Arch Intern Med 1993, 153:1917-1923.
11. Lancaster T., Stead L.F. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev 2000, (2). Art. No.: CD001009. DOI: 001010.001002/14651858.CD14001009.
12. Glover E.D., Laflin M.T., Schuh K.J., et al. A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction 2007, 102:795-802.
13. Nemeth-Coslett R., Henningfield J.E., O'Keeffe M.K., Griffiths R.R. Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology (Berl) 1986, 88:420-425.
14. Stolerman I.P., Goldfarb T., Fink R., Jarvik M.E. Influencing cigarette smoking with nicotine antagonists. Psychopharmacologia 1973, 28:247-259.
15. Pomerleau C.S., Pomerleau O.F., Majchrzak M.J. Mecamylamine pretreatment increases subsequent nicotine self-administration as indicated by changes in plasma nicotine level. Psychopharmacology (Berl) 1987, 91:391-393.
16. Rose J.E., Sampson A., Levin E.D., Henningfield J.E. Mecamylamine increases nicotine preference and attenuates nicotine discrimination. Pharmacol Biochem Behav 1989, 32:933-938.
17. Tennant F., Tarver A., Rawson R. Clinical evaluation of mecamylamine for withdrawal from nicotine dependence 1984, U.S. Department of Health and Human Services, Rockville, MD.
18. Jacob P., Wu S., Yu L., Benowitz N.L. Simultaneous determination of mecamylamine, nicotine, and cotinine in plasma by gas chromatography-mass spectrometry. J Pharm Biomed Anal 2000, 23:653-661.
19. Kataoka H., Inoue R., Yagi K., Saito K. Determination of nicotine, cotinine, and related alkaloids in human urine and saliva by automated in-tube solid-phase microextraction coupled with liquid chromatography-mass spectrometry. J Pharm Biomed Anal 2009, 49:108-114.
20. Gabr R.Q., Elsherbiny M.E., Somayaji V., Pollak P.T., Brocks D.R. A liquid chromatography-mass spectrometry method for nicotine and cotinine; utility in screening tobacco exposure in patients taking amiodarone. Biomed Chromatogr 2011, 25:1124-1131.
21. Hoofnagle A.N., Laha T.J., Rainey P.M., Sadrzadeh S.M. Specific detection of anabasine, nicotine, and nicotine metabolites in urine by liquid chromatography-tandem mass spectrometry. Am J Clin Pathol 2006, 126:880-887.
22. Tuomi T., Johnsson T., Rejula K. Analysis of nicotine, 3-hydroxycotinine, cotinine, and caffeine in urine of passive smokers by HPLC-tandem mass spectrometry. Clin Chem 1999, 45:2164-2172.
23. Meger M., Meger-Kossien I., Schuler-Metz A., Janket D., Scherer G. Simultaneous determination of nicotine and eight nicotine metabolites in urine of smokers using liquid chromatography-tandem mass spectrometry. J Chromatogr B 2002, 778:251-261.
24. Xu X., Iba M.M., Weisel C.P. Simultaneous and sensitive measurement of anabasine, nicotine, and nicotine metabolites in human urine by liquid chromatography-tandem mass spectrometry. Clin Chem 2004, 50:2323-2330.
25. Hu C.-W., Chang Y.-Z., Wang H.-W., Chao M.-R. High-throughput simultaneous analysis of five urinary metabolites of areca nut and tobacco alkaloids by isotope-dilution liquid chromatography-tandem mass spectrometry with on-line solid-phase extraction. Cancer Epidemiol Biomarkers Prev 2010, 19:2570-2581.
26. Marclay F., Saugy M. Determination of nicotine and nicotine metabolites in urine by hydrophilic interaction chromatography-tandem mass spectrometry: Potential use of smokeless tobacco products by ice hockey players. J Chromatogr A 2010, 1217:7528-7538.
27. Jacob P., Yu L., Duan M., Ramos L., Yturralde O., Benowitz N.L. Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. J Chromatogr B 2011, 879:267-276.
28. Krouwer J.S., Rabinowitz R. How to improve estimates of imprecision. Clin Chem 1984, 30:290-292.
29. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003, 75:3019-3030.
30. Hukkanen J., Jacob P., Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005, 57:79-115.
31. Rangiah K., Hwang W.T., Mesaros C., Vachani A., Blair I.A. Nicotine exposure and metabolizer phenotypes from analysis of urinary nicotine and its 15 metabolites by LC-MS. Bioanalysis 2011, 3:745-761.
32. Debruyne D., Sobrio F., Hinschberger A., Camsonne R., Coquerel A., Barre L. Short-term pharmacokinetics and brain distribution of mecamylamine as a preliminary to carbon-11 labeling for nicotinic receptor investigation. J Pharm Sci 2003, 92:1051-1057.
33. Maurer H.H. Advances in analytical toxicology: the current role of liquid chromatography-mass spectrometry in drug quantification in blood and oral fluid. Anal Bioanal Chem 2005, 381:110-118.